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Abstract 
As has been well recognized, methotrexate (MTX) leads to a state of 
immunosuppression and can provide a basis for the development of 
lymphoproliferative disorders (LPDs). MTX-associated LPDs can affect 
nodal sites as well as extranodal sites, though the manifestation of an LPD 
in the form of multiple pulmonary nodules is rare. Here, we report two cases 
of MTX-associated LPD with multiple bilateral pulmonary nodules, which 
was a finding suggestive of lung cancer, and bilateral cervical 
lymphadenopathy. After withdrawal of MTX, the multiple bilateral 
pulmonary nodules and bilateral cervical lymphadenopathy disappeared 
without chemotherapy in both cases. From these results, patients with 
pulmonary nodules and cervical lymphadenopathy should be examined for 
head and neck malignant tumors. Also, physicians should carefully check 
the administration of MTX. In patients with an MTX-associated LPD, we 
need to make an early diagnosis and consider discontinuing the 
administration of MTX as soon as possible.  
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Introduction 
Methotrexate (MTX) is an effective immunosuppressive drug that is 
widely administered to patients with autoimmune diseases including 
rheumatoid arthritis (RA). In 1991, reported for the first time, a patient 
with RA who was taking low-dose weekly MTX developed lymphoma [1]. 
These days, there are a lot of reports that MTX leads to a state of 
immunosuppression and can provide a basis for the development of 
lymphoproliferative disorders (LPDs)[2-6]. MTX-associated LPDs can affect 
nodal sites as well as extranodal sites. Forty to fifty percent of the patients 
with MTX-associated LPDs have extranodal sites[7]. The skin, lungs, 
gastrointestinal tract, spleen, oral cavity, and kidneys may be involved as 
the extranodal LPD sites [3]. In the head and neck regions, the palatine 
tonsil, epipharynx, gingiva, tongue, salivary gland, thyroid gland, and nasal 
cavity have also been reported as the extranodal LPD sites [4, 5, 8].  
The manifestation of an LPD in the form of multiple pulmonary 
nodules is rare. Here, we report two cases of MTX-associated LPD with 
bilateral cervical lymphadenopathy and multiple bilateral pulmonary 




Before being referred to our hospital, a 67-year-old male had 
complained of bilateral parotid swelling for one week. He had a medical 
history of RA, diabetes, hypertension, stenosis of the left internal carotid 
artery, and right Bell’s palsy. He had been receiving MTX (14 mg/week for 
10 years), prednisolone (PSL), folic acid, and cilostazol. He did not have a 
history of smoking. He did not present with fever. A physical examination 
revealed superficial lymphadenopathy in the bilateral neck region, 
submandibular adenopathy, and parotid gland enlargement. He had no 
bilateral facial nerve palsy.  
Laboratory data showed an LDH of 209 IU/L (within the normal 
range). The level of soluble interleukin-2 receptor was elevated at 
1,180 U/mL (normal: 127–582 U/mL), and the C-reactive protein level was 
also elevated at 2.0 mg (normal: <0.3 mg). The serum anti-SSA and anti-
SSB antibodies were negative. 
Computed tomography (CT) demonstrated multiple bilateral 
pulmonary nodules (0.6–2.7 cm diameter), which was a finding suggestive of 
lung cancer (Fig. 1A), mediastinal lymphadenopathy, and left hilar 
adenopathy. Contrast-enhanced neck magnetic resonance imaging (MRI) 
demonstrated multiple nodules of the bilateral submandibular gland and 
parotid gland, and bilateral cervical lymphadenopathy (Fig. 1B).  
A fine needle aspiration was performed on nodules of the left 
submandibular gland and left parotid gland. The cytological specimen 
showed Class II. For a definite diagnosis, the right submandibular gland 
was removed under general anesthesia. MTX was discontinued before 
surgery. The bilateral superficial lymphadenopathy, submandibular 
adenopathy, and parotid gland enlargement improved rapidly after the 
cessation of the drug. A pathological examination showed the possibility of 
subsidence of necrotizing lesions after the withdrawal of the drug, and it 
also confirmed infiltrating foam cells and small lymphoid cells around the 
necrotizing lesions.  
Five months after the surgery, CT demonstrated that the multiple 
bilateral pulmonary nodules, mediastinal lymphadenopathy, and left hilar 
adenopathy disappeared.  
 
Case 2 
Before being referred to our hospital, a 74-year-old female had 
complained of right pharyngeal discomfort including mild pain, which got 
worse during swallowing, for two months. She had a medical history of RA 
and osteoporosis. She had been receiving MTX (14 mg/week for 10 years), 
folic acid, penicillamine, sodium risedronate hydrate, and vitamin B 
complex. She did not have a history of smoking. She did not present with 
fever and fatigue. In nasal and pharyngo-laryngeal examinations with a 
flexible endoscope, there was an ulcerated elevated lesion with a white mass 
at the right posterior part of the tongue (Fig. 2A). A biopsy was performed in 
this region.  
Laboratory data showed an LDH of 208 IU/L and a soluble 
interleukin-2 receptor level of 449 U/mL, both within the normal range. The 
C-reactive protein level was elevated at 1.7 mg (normal: <0.3 mg). Contrast-
enhanced CT demonstrated multiple bilateral pulmonary nodules (0.4–
2.6 cm diameter) and bilateral cervical lymphadenopathy (Fig. 2B, C).  
The results of a pathological examination of the ulcerated elevated 
lesion showed granulation tissue. For a definite diagnosis, the right lymph 
node was removed under local anesthesia. In a pathological examination, 
there was a collapsed basic structure of the lymph node with medium-sized 
atypical lymphoid cells (Fig. 3A). In situ hybridization of an Epstein-Barr 
virus-encoded small RNA (EBER) revealed that the atypical lymphoid cells 
were positive for EBER (Fig. 3B). A definitive diagnosis of MTX-associated 
LPD was established.  
One month after withdrawal of the drug after the lymph node biopsy, 
CT demonstrated that the multiple bilateral pulmonary nodules and 
bilateral cervical lymphadenopathy had disappeared. 
 
Discussion  
MTX-associated LPDs are categorized as either iatrogenic or 
immunodeficiency-associated diseases in the recent World Health 
Organization (WHO) classification of lymphoid neoplasms[7]. MTX-
associated LPDs are defined as lymphoma or lymphomatoid lesions 
identified in an MTX-induced immunosuppressed state. Tokuhira, et al. 
found that there were three patterns of LPD development[6]. In the first 
group, MTX-Regressive-LPDs, LPD regression occurred after withdrawal of 
MTX. In the second, MTX-Persistent-LPDs, LPD persisted after MTX 
withdrawal. In the last, Other-Mediated-LPDs, LPD developed only after 
MTX. Our two cases fit MTX-Regressive-LPDs. 
Although the mechanism of onset is unknown, the combination of 
immunodeficiency as a result of RA and the immunosuppressive effect of 
MTX has been implicated in the pathogenesis of MTX-LPD. In RA, self-
reactive T cells of a specific clone stimulate B cells that produce 
autoantibodies, such as rheumatoid factor. When MTX is administered, its 
immunosuppressive effect reactivates viral infections, including subclinical 
infections, and it is hypothesized that this triggers clonal proliferation of 
cells[9]. 
In particular, EBV is considered to be an important viral infection 
associated with LPD that develops in the context of rheumatological 
diseases. Activation of EBV is identified in the majority of MTX-LPD 
cases[5], including Case 2. Many reports have indicated that EBV 
contributes to the development of MTX-associated LPDs and that MTX-
associated LPDs regress spontaneously after withdrawal of MTX[1, 2, 4, 7]. 
There was an EBV infection in the LPD in Case 2. EBV infections were 
observed in 37.7% of cases (40 of 106 cases)[7]. LPDs with spontaneous 
regression had a higher EBV positivity than LPDs without regression [10]. 
After the withdrawal of MTX, our both patients had a smooth remission 
fortunately, although there was no EBV infection in Case 1. If the 
withdrawal of MTX had not achieved remission of the LPD, chemotherapy 
like R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and 
prednisone) would be needed [11].  
The histologic patterns of the MTX-associated LPDs were 
heterogeneous and identical to several types of lymphomas. Mariette et al. 
reported 18 types of non-Hodgkin lymphoma (NHL) (16 B-cell NHLs and 2 
T-cell NHLs) and 7 types of Hodgkin disease (HD) in 25 MTX-associated 
LPDs [5]. In Japan, Hoshida et al. reported 42 NHL types (38 B-cell, 3 T-
cell, and 1 natural killer cell) and 6 HD types in 48 MTX-associated LPDs 
[4]. B-cell NHL and HD make up the majority of the histologic patterns of 
MTX-associated LPDs. Our cases are not compatible with a particular 
histological type of lymphoma. After the withdrawal of MTX, we did a biopsy 
in both cases, and the MTX-associated LPDs may have regressed 
spontaneously. It is difficult to distinguish MTX-Regressive-LPDs from 
MTX-Persistent-LPDs in advance. For the choice of chemotherapy of MTX-
Persistent-LPDs, we believe tissue examination is necessary. If LPD 
regression occurred after withdrawal of MTX, it is difficult to diagnose LPD, 
and that is why tissue examination should be done before cessation of MTX, 
if it is possible. The decision regarding operation was done 10 days before 
the day of the operation in Case 1. For preventing further deterioration, we 
decided to perform the operation after withdrawal of MTX.  
The reported median age at diagnosis of an MTX-associated LPD is 
60–70 years, and there is a female preponderance in MTX-associated LPDs 
[4, 5]. The mean duration of MTX treatment is over four years in the 
reported cases. However, there is no association between the onset of an 
MTX-associated LPD and the method of administration of MTX (dose and/or 
duration). A patient could develop an MTX-associated LPD a few months 
after starting to use MTX [4, 5]. 
Image findings of pulmonary lesions of MTX-LPD are nodular 
density, infiltrative shadow, ground-glass pattern, and so on about CT scan. 
These are non-specific findings, and that is why it is necessary to make a 
final differential diagnosis by counting laboratory examinations such as 
tumor marker, pathological findings, and image findings of other body parts. 
In Case 2, it is unconventional way of progress for lung cancer to find no 
mediastinal lymphadenopathy and hilar adenopathy, but cervical 
lymphadenopathy. 
To the best of our knowledge, only 14 cases of MTX-associated LPD 
with multiple pulmonary nodules have been reported in the English 
literature. Table 1 summarizes the clinicopathological features of these 
cases. The mean age ± standard deviation of the disease is 62.8 ± 11.9 years 
old (Table 1). The median MTX intake duration was 5 years (range: several 
weeks to 17 years). The patients exhibited involvement of the spleen (4/14), 
liver (2/14), ileum (1/14), skin (1/14), central nervous system (1/14), adrenal 
gland (1/14), retromolar triangle (1/14), kidney (1/14), and retroperitoneal 
lesions (1/14). The histologic patterns are diffuse large B-cell lymphoma 
(5/14), lymphomatoid granulomatosis (LYG) (4/14), extranodal NK/T-cell 
lymphoma (1/14), CD8-positive T-cell LPD (1/14), and non-classifiable 
patterns (3/14). LYG (B-cell derived lymphoproliferative disease) is rare; 
however, it often presents as pulmonary nodular lesions with a 
histopathology of lymphatic invasion of the vascular wall [12]. Its 
development is thought to be associated with the immunosuppressive state 
[13]. LYG is a less-aggressive LPD, and regression of LYG following the 
discontinuation of MTX has been reported [12-14]. The only reported fatal 
case was an RA patient who was receiving MTX therapy and developed both 
LYG and interstitial pneumonia with the pathological features of diffuse 
alveolar damage [15]. Aside from this fatal case, the patients in the other 13 
cases were alive after the cessation of MTX. Chemotherapy was needed in 
three cases, and an upper lobectomy was needed in two cases as additional 
therapy.  
The multiple nodules demonstrated in the chest CT suggest multiple 
metastatic cancers or alveolar cell carcinoma in general. Another differential 
diagnosis issue that should be considered is the possibility of organizing 
pneumonia (OP), either primary or secondary to MTX or other disease-
modifying antirheumatic drugs (DMARDs) [3]. Although all manifestations 
and pathological results point to MTX-associated LPDs, we should 
remember the possibility of OP in the subsequent follow-up on a patient 
after the regression of lung nodules. It is very important to carefully check 
for the presence of an MTX-associated LPD in a patient who has been 
receiving MTX, has lesions like cervical lymphadenopathy in the head and 
neck regions, and also has lung tumors suspected to have metastatic lung 
cancer, before considering an aggressive treatment.  
 
Conclusion  
We experienced two cases of MTX-associated LPD with multiple 
bilateral pulmonary nodules and bilateral cervical lymphadenopathy. Head 
and neck malignant tumors and/or lung cancer was suspected in the 
patients. From this experience, even though the manifestation of an MTX-
associated LPD in the form of multiple pulmonary nodules is rare, 
physicians should carefully check for the presence of an MTX-associated 
LPD.  
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Figure legend 
Fig. 1A: Chest CT at the initial visit (black arrows, multiple nodular lung 
lesions). 
Fig. 1B: Contrast-enhanced neck MRI at the initial visit (black arrows, ring-
enhancing lesion of the bilateral submandibular gland; white arrows, 
bilateral cervical lymphadenopathy). 
 
Fig. 2A: Endoscopic finding in the pharynx at the initial visit (black arrow, 
ulcerated elevated lesion with a white mass at the right posterior part of the 
tongue). 
Fig. 2B, C: Contrast-enhanced neck-chest CT at the initial visit (black 
arrows, bilateral cervical lymphadenopathy; white arrows, multiple nodular 
lung lesions). 
 
Fig. 3A: Microscopic findings. Histopathology of a biopsied lymph node 
showing a collapsed basic structure of the lymph node with medium-sized 
atypical lymphoid cells (hematoxylin and eosin staining). 
Fig. 3B: In situ hybridization findings. An Epstein-Barr virus-encoded small 
RNA (EBER) revealed that atypical lymphoid cells were positive for EBER.  
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